File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy of single-session radiofrequency ablation (RFA) in rendering euthyroidism for persistent/relapsed Graves’ disease, a pilot study

TitleEfficacy of single-session radiofrequency ablation (RFA) in rendering euthyroidism for persistent/relapsed Graves’ disease, a pilot study
Authors
KeywordsGraves’ disease
Iodine
Radiofrequency ablation
Thyroidectomy
Ultrasonography
Issue Date2023
Citation
European Radiology, 2023, v. 33, n. 9, p. 6534-6544 How to Cite?
AbstractObjectives: Graves’ disease (GD) is the most common cause of hyperthyroidism. Antithyroid drug (ATD) is often the first-line treatment but > 50% patients suffer a relapse when ATD is discontinued. Surgery or radioiodine remains the current options of definitive treatment in these patients. This pilot study examined the short-term efficacy of single-session thyroid radiofrequency ablation (RFA) as a novel definitive treatment for persistent/relapsed GD. Methods: Consecutive patients with persistent/relapsed GD requiring ATD were considered. Those with a clear surgical indication, either thyroid lobe volume ≥ 20 mL; those who were pregnant or lactating; and those who had any severe medical conditions that would pose extra treatment risks were excluded. Eligible patients received ultrasound-guided RFA of the entire bulk of thyroid gland. Thyroid function tests were monitored bi-monthly. The primary outcome was disease remission rate, defined as a state of biochemical euthyroidism or hypothyroidism without ATD. Secondary outcomes were complication rates. Results: Of the 68 patients considered, 15 (22.1%) patients were eligible. Most were females (93.3%). The median age was 37 (IQR 31–48) years old. The disease remission rates were 79.0% at 6 months and 73.3% at 12 months. Among the 4 patients who relapsed after RFA, three required less ATD dose than before RFA. RFA was well-tolerated in the ambulatory setting. There were no vocal cord palsy, skin burn, hematoma, or thyroid storm after RFA. Conclusions: In well-selected patients, single-session RFA of the thyroid gland may be a potential treatment for patients with persistent/relapsed GD. It is a safe and well-tolerated ambulatory procedure. Key Points: • Radiofrequency ablation of the thyroid gland is an efficacious treatment for persistent/relapsed Graves’ disease in well-selected patients. • Radiofrequency ablation of the thyroid gland for the treatment of persistent/relapsed Graves’ disease is a safe and well-tolerated ambulatory procedure. • Radiofrequency ablation of the thyroid gland may be a potential alternative treatment for well-selected patients with persistent/relapsed GD who do not wish to undergo either thyroidectomy or radioactive iodine or continue antithyroid drugs.
Persistent Identifierhttp://hdl.handle.net/10722/336902
ISSN
2023 Impact Factor: 4.7
2023 SCImago Journal Rankings: 1.656
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorFung, Man Him Matrix-
dc.contributor.authorLang, Brian Hung Hin-
dc.date.accessioned2024-02-29T06:57:19Z-
dc.date.available2024-02-29T06:57:19Z-
dc.date.issued2023-
dc.identifier.citationEuropean Radiology, 2023, v. 33, n. 9, p. 6534-6544-
dc.identifier.issn0938-7994-
dc.identifier.urihttp://hdl.handle.net/10722/336902-
dc.description.abstractObjectives: Graves’ disease (GD) is the most common cause of hyperthyroidism. Antithyroid drug (ATD) is often the first-line treatment but > 50% patients suffer a relapse when ATD is discontinued. Surgery or radioiodine remains the current options of definitive treatment in these patients. This pilot study examined the short-term efficacy of single-session thyroid radiofrequency ablation (RFA) as a novel definitive treatment for persistent/relapsed GD. Methods: Consecutive patients with persistent/relapsed GD requiring ATD were considered. Those with a clear surgical indication, either thyroid lobe volume ≥ 20 mL; those who were pregnant or lactating; and those who had any severe medical conditions that would pose extra treatment risks were excluded. Eligible patients received ultrasound-guided RFA of the entire bulk of thyroid gland. Thyroid function tests were monitored bi-monthly. The primary outcome was disease remission rate, defined as a state of biochemical euthyroidism or hypothyroidism without ATD. Secondary outcomes were complication rates. Results: Of the 68 patients considered, 15 (22.1%) patients were eligible. Most were females (93.3%). The median age was 37 (IQR 31–48) years old. The disease remission rates were 79.0% at 6 months and 73.3% at 12 months. Among the 4 patients who relapsed after RFA, three required less ATD dose than before RFA. RFA was well-tolerated in the ambulatory setting. There were no vocal cord palsy, skin burn, hematoma, or thyroid storm after RFA. Conclusions: In well-selected patients, single-session RFA of the thyroid gland may be a potential treatment for patients with persistent/relapsed GD. It is a safe and well-tolerated ambulatory procedure. Key Points: • Radiofrequency ablation of the thyroid gland is an efficacious treatment for persistent/relapsed Graves’ disease in well-selected patients. • Radiofrequency ablation of the thyroid gland for the treatment of persistent/relapsed Graves’ disease is a safe and well-tolerated ambulatory procedure. • Radiofrequency ablation of the thyroid gland may be a potential alternative treatment for well-selected patients with persistent/relapsed GD who do not wish to undergo either thyroidectomy or radioactive iodine or continue antithyroid drugs.-
dc.languageeng-
dc.relation.ispartofEuropean Radiology-
dc.subjectGraves’ disease-
dc.subjectIodine-
dc.subjectRadiofrequency ablation-
dc.subjectThyroidectomy-
dc.subjectUltrasonography-
dc.titleEfficacy of single-session radiofrequency ablation (RFA) in rendering euthyroidism for persistent/relapsed Graves’ disease, a pilot study-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00330-023-09620-1-
dc.identifier.pmid37036479-
dc.identifier.scopuseid_2-s2.0-85152369549-
dc.identifier.volume33-
dc.identifier.issue9-
dc.identifier.spage6534-
dc.identifier.epage6544-
dc.identifier.eissn1432-1084-
dc.identifier.isiWOS:000966714400002-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats